The company begins Phase 1 trials of oral GAL-101, targeting amyloid beta aggregation. Promising safety and efficacy in ...

SPI, a novel method integrated with AlphaFold3, to identify causal protein biomarkers and predict their 3D structural changes ...

The Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for the ...

Demonstrates MS Analysis Technology, Recently Secured FDA 510(k) Clearance Introduces 'Neurophet AQUA AD,' a Total Solution ...

Viehbacher, "Biogen") announced today that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aß) ...

Researchers at Baylor College of Medicine, working with other institutions, have made a breakthrough in understanding how ...

The disease is characterized by two hallmark changes in the brain: plaques made of a protein called beta-amyloid and tangles ...

A number of firms have modified their ratings and price targets on shares of Voyager Therapeutics (NASDAQ: VYGR) recently: 12/2/2024 – Voyager Therapeutics is now covered by analysts at Citigroup Inc.

Just as Eisai notches wins in its campaign for lecanemab approval around the world—last month in the European Union, this week in Mexico—a dozen research and clinical leaders called on the U.S. FDA ...

A study from Arizona State University links glyphosate, a widely used herbicide, to Alzheimer’s-like brain damage and ...

Alzheimer’s disease (AD), a devastating brain disorder affecting millions globally, has long been a puzzle for researchers.

Sleep is that elusive friend that we sometimes overlook, as if we were superhumans capable of functioning on 5 hours of rest ...